Experienced in Retrograde Ejaculation

Jens Bedke

Hoppe Seyler Street 3, 
Tuebingen, BW, DE 
Experienced in Retrograde Ejaculation
Hoppe Seyler Street 3, 
Tuebingen, BW, DE 
OverviewLocationsClinical Research

Overview

Jens Bedke practices in Tuebingen, Germany. Mr. Bedke is rated as an Experienced expert by MediFind in the treatment of Retrograde Ejaculation. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Prostatectomy.

His clinical research consists of co-authoring 297 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Hoppe Seyler Street 3, Tuebingen, BW 72076, Germany
Other Locations
Kuno Fischer Str. 8, Berlin, BE 14057, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Open vs Robotic Assisted Partial Nephrectomy
Open vs Robotic Assisted Partial Nephrectomy
Enrollment Status: Terminated
Publish Date: June 17, 2025
Intervention Type: Other, Device
Study Phase: Not Applicable
A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)
A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma
Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma
Enrollment Status: Terminated
Publish Date: February 13, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
View 3 Less Clinical Trials

297 Total Publications

Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Journal: Nature medicine
Published: July 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bedke's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 19 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile